Twist Bioscience Corporation and Ginkgo Bioworks Revise Collaboration

Published: 2025-05-08 08:00:00 ET DNA

Published on 05/08/2025 at 08:00, updated on 05/08/2025 at 10:06

Twist Bioscience Corporation and Ginkgo Bioworks announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. Ginkgo will receive preferential pricing for DNA products with no required minimum purchase volume. As credit against the agreement signed in 2022, Twist receives licenses and assignments for certain long DNA and other technology as well as related reagents to complement its existing DNA synthesis portfolio of products, while Ginkgo retains the rights to practice the IP transferred to Twist.

This strategic acquisition complements Twist's existing comprehensive portfolio of DNA synthesis products, further strengthening its position as a leader in the field.